Using single-cell and spatially resolved analysis of human NSCLCs, we have previously characterized local effector T cell dysfunction and found that evidence of enhanced T cell proliferation, terminal differentiation, and upregulation of immune-inhibitory receptors were associated with reduced sensitivity to PD-1 axis blockers among patients with NSCLC (10–12). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.